Compositions and methods for reprogramming skin into insulin-producing tissue - Patents.com
Reprogramming skin cells with Pdx1, Ng3, and Tcf3 nucleic acid sequences addresses the scarcity of insulin-producing cells in Type 1 diabetes, achieving controlled glycemia through intracellular delivery and extracellular vesicle-assisted methods.
Patent Information
- Application Number
- JP2021504804
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-08-01
- Filing Date
- 2019-08-01
- Publication Date
- 2024-12-04
- Estimated Expiration
- 2039-08-01
AI Technical Summary
There is a need for improved compositions and methods to replenish endogenous insulin-producing cells in Type 1 diabetes, as current treatments like islet or pancreas transplantation are limited by organ scarcity.
Reprogramming skin cells into insulin-producing cells using a polynucleotide comprising nucleic acid sequences encoding Pdx1, Ng3, and Tcf3 (PMN-T factor) delivered intracellularly, optionally via non-viral vectors like a recombinant bacterial plasmid, and utilizing extracellular vesicles to facilitate the reprogramming process.
The method effectively reprograms skin cells into insulin-producing cells, achieving controlled glycemia in diabetic subjects by reducing blood glucose levels to normal ranges.
Smart Images

Figure 0007594298000001 
Figure 0007594298000002 
Figure 0007594298000003
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 62 / 713,239, filed August 1, 2018, which is incorporated herein by reference in its entirety.
[0002] Sequence Listing This application contains a Sequence Listing that has been filed electronically as an ASCII.txt file entitled "321501-2330 Sequence Listing_ST25," created on August 1, 2019. The contents of the Sequence Listing are incorporated herein in their entirety. [Background technology]
[0003] Type 1 diabetes (T1D) is a chronic, debilitating autoimmune disease that targets pancreatic beta cells, reducing beta cell mass and resulting in insufficient insulin production. While the exact etiology of T1D remains unclear, it remains widespread among young children and lacks a viable treatment, despite being one of the most common endocrine disorders. Successful islet or pancreas transplantation can reduce some of the complications of T1D. However, organ scarcity severely limits this approach. Therefore, improved compositions and methods for replenishing endogenous insulin-producing cells are needed. Summary of the Invention [Problem to be solved by the invention]
[0004] Disclosed herein are compositions and methods for reprogramming skin cells into insulin-producing cells both in vitro and in vivo. One embodiment discloses a polynucleotide comprising two or more nucleic acid sequences encoding Pdx1, Ng3, Mafa, and Tcf3 ("PMN-T factors"). In some embodiments, the PMN-T factors are mammalian proteins, such as human proteins. [Means for solving the problem]
[0005] In some embodiments, the PMN-T factors are expressed in approximately equal ratios. In some embodiments, the Pdx1, Ng3, Mafa, and Tcf3 proteins are expressed in approximately 1:1:1:1, 2:1:1:1, 1:2:1:1, 1:1:2:1, 1:1:1:2, 2:2:1:1, 2:1:2:1, 2:1:1:2, 1:2:2:1, 1:1:2:2, 1:2:1:2, 3:1:1:1, 1:3:1 :1, 1:1:3:1, 1:1:1:3, 3:2:1:1, 3:1:2:1, 3:1:1:2, 1:3:2:1, 1:1:3:2, 1:3:1:2, 2:3:1:1, 2:1:3:1, 2:1:1:3, 1:2:3:1, 1:1:2:3, 1:2:1:3 (Pdx1:Ng3:Mafa:Tcf3) ratios.
[0006] Also disclosed is a non-viral vector containing the polynucleotide of the present disclosure.In certain embodiments, the vector is a recombinant bacterial plasmid.For example, in some embodiments, the non-viral vector has a pCDNA3 backbone.In some embodiments, the vector comprises an internal ribosome entry site (IRES).
[0007] Also disclosed is a method for reprogramming skin cells into insulin-producing cells, comprising intracellularly delivering into the skin cells a polynucleotide comprising a nucleic acid sequence encoding Pdx1, Ng3, Mafa, and Tcf3. Each of the PNM-T factors can be delivered simultaneously, sequentially, or any combination thereof. In some embodiments, the method first comprises intracellularly delivering into the skin cells a polynucleotide comprising a nucleic acid sequence encoding Pdx1. The method can then comprise, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 days later, intracellularly delivering into the skin cells a polynucleotide comprising a nucleic acid sequence encoding Ng3, Mafa, and Tcf3. In some embodiments, the method first comprises intracellularly delivering into the skin cells a polynucleotide comprising a nucleic acid sequence encoding Tcf3. The method can then comprise, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 days later, intracellularly delivering into the skin cells a polynucleotide comprising a nucleic acid sequence encoding Ng3, Mafa, and Pdx1. In some embodiments, the method includes first intracellularly delivering into skin cells a polynucleotide comprising a nucleic acid sequence encoding Mafa. Then, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 days later, the method includes intracellularly delivering into skin cells polynucleotides comprising nucleic acid sequences encoding Ng3, Tcf3, and Pdx1. In some embodiments, the method includes first intracellularly delivering into skin cells a polynucleotide comprising a nucleic acid sequence encoding Ng3. Then, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 days later, the method includes intracellularly delivering into skin cells polynucleotides comprising nucleic acid sequences encoding Mafa, Tcf3, and Pdx1.
[0008] In some embodiments, after transfecting a nucleic acid sequence encoding PMN-T factor into target cells, the cells can load the transfected gene (e.g., cDNA) into EVs, which can then assist other skin cells in forming insulin-producing cells. Thus, a method for reprogramming skin cells into insulin-producing cells is also disclosed, comprising exposing the skin cells to extracellular vesicles produced from cells containing or expressing PMN-T factor.
[0009] In these embodiments, polynucleotides and compositions can be delivered intracellularly to skin cells or donor cells by gene guns, microparticles or nanoparticles suitable for such delivery, transfection by electroporation, three-dimensional nanochannel electroporation, tissue nanotransfection devices, liposomes suitable for such delivery, or deep local tissue nanoelectroinjection devices. In some of these embodiments, polynucleotides can be incorporated into non-viral vectors, such as bacterial plasmids. In some embodiments, viral vectors can be used. For example, polynucleotides can be incorporated into viral vectors, such as adenoviral vectors. However, in other embodiments, polynucleotides are not delivered virally.
[0010] Also disclosed are methods for treating diabetes in a subject, comprising reprogramming an effective amount of skin cells in the subject into insulin-producing cells using the methods disclosed herein. For example, in some embodiments, the subject has insulin-dependent diabetes. In some embodiments, the subject has insulin-resistant diabetes. In some embodiments, the subject has controlled blood glucose (not hyperglycemia) during treatment. For example, in some embodiments, the subject has a fasting blood glucose level of less than 180, 170, 160, 150, 140, 130, 120, or 110 mg / dL during treatment, including between 70 and 130 mg / dL during treatment.
[0011] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims. [Brief explanation of the drawings]
[0012] [Figures 1A-1E] Graphs showing blood glucose in mice with type 1 diabetes induced by streptozotocin injection after treatment with PBS (Figure 1A), PNM factor (Figure 1B), PNM-T factor (Figure 1C), Tcf3 alone (Figure 1D), or Tcf3 on day 1 and PNM on day 7 (Figure 1E) from week 1 to week 14. DETAILED DESCRIPTION OF THE INVENTION
[0013] Before describing the present disclosure in more detail, it is to be understood that this disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.
[0014] Where a range of values is provided, unless the context clearly dictates otherwise, it is understood that each intervening value (to the tenth of the unit of the lower limit) between the upper and lower limit of that range, and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.
[0015] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of this disclosure, the preferred methods and materials are described herein.
[0016] All publications and patents cited herein are incorporated by reference as if each individual publication or patent was specifically and individually indicated to be incorporated by reference and as if each individual publication or patent were incorporated by reference to disclose and describe the methods and / or materials in connection with which the publication is cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
[0017] As will be apparent to one of ordinary skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has distinct components and features which may be readily separated from, or combined with, the features of any of the other several embodiments without departing from the scope or spirit of the disclosure. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.
[0018] Embodiments of the present disclosure employ, unless otherwise indicated, chemical, biological and other techniques within the skill of the art.
[0019] The following examples are presented to provide those of ordinary skill in the art with a complete disclosure and description of how to practice the methods and use the probes disclosed and claimed herein. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperatures, etc.), but some errors and deviations should be accounted for. Unless otherwise indicated, parts are parts by weight, temperatures are in °C, and pressures are at or near atmospheric. Standard temperature and pressure are defined as 20 °C and 1 atmosphere.
[0020] Before describing embodiments of the present disclosure in detail, it is to be understood that, unless otherwise indicated, the present disclosure is not limited to particular materials, reagents, reaction materials, manufacturing processes, etc., as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. In the present disclosure, where it is logically possible to perform steps in a different order, this can be done.
[0021] It must be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0022] definition The term "subject" refers to any individual who is the target of administration or treatment. A subject can be a vertebrate, e.g., a mammal. Thus, a subject can be a human or veterinary patient. The term "patient" refers to a subject under the care of a clinician, e.g., a physician.
[0023] The term "therapeutically effective" refers to the amount of composition used being sufficient to ameliorate one or more causes or symptoms of a disease or disorder. Such amelioration requires only a reduction or alteration, not necessarily elimination.
[0024] The term "pharmaceutically acceptable" refers to compounds, materials, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with human or animal tissues without excessive toxicity, irritation, allergic response, and other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0025] The term "carrier" means a compound, composition, substance, or structure that is combined with a compound or composition to aid or facilitate the preparation, storage, administration, delivery, efficacy, selectivity, or any other property of the compound or composition for its intended use or purpose. For example, a carrier can be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject.
[0026] The term "treatment" refers to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, condition, or disorder. This term includes active treatment, i.e., treatment specifically directed at ameliorating the disease, condition, or disorder, and also includes causal treatment, i.e., treatment directed at eliminating the cause of the associated disease, condition, or disorder. Furthermore, this term includes palliative treatment, i.e., treatment designed to alleviate symptoms rather than cure the disease, condition, or disorder; prophylactic treatment, i.e., treatment directed at minimizing or partially or completely inhibiting the onset of the associated disease, condition, or disorder; and supportive treatment, i.e., treatment used to supplement another specific treatment directed at ameliorating the associated disease, condition, or disorder.
[0027] The term "inhibit" refers to a decrease in an activity, response, pathology, disease, or other biological parameter. This can include, but is not limited to, the complete elimination of the activity, response, pathology, or disease. It can also include, for example, a 10% decrease in the activity, response, pathology, or disease compared to native or control levels. Thus, the decrease can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount therebetween, compared to native or control levels.
[0028] The term "polypeptide" refers to amino acids linked together by peptide bonds or modified peptide bonds, e.g., peptide isosteres, and may contain modified amino acids other than the 20 gene-encoded amino acids. Polypeptides may be modified by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains, and the amino or carboxyl termini. The same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. A given polypeptide may also contain multiple types of modifications. Modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent cross-linking or cyclization, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, disulfide bond formation, demethylation, cysteine or pyroglutamate formation, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pergylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, and the addition of amino acids to proteins via transfer RNA (e.g., arginylation). (See Proteins - Structure and Molecular Properties 2nd Ed., TECreighton, W.H. Freeman and Company, New York (1993); Posttranslational Covalent Modification of Proteins, B.C. Johnson, Ed., Academic Press, New York, pp. 1-12 (1983)).
[0029] As used herein, the term "amino acid sequence" refers to a list of abbreviations, letters, symbols, or words representing amino acid residues. Amino acid abbreviations used herein are the conventional one-letter codes for amino acids, and are represented as follows: A, alanine; B, asparagine or aspartic acid; C, cysteine; D, aspartic acid; E, glutamate, glutamic acid; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine; Z, glutamine or glutamic acid.
[0030] As used herein, the term "nucleic acid" refers to a naturally occurring or synthetic oligonucleotide or polynucleotide capable of hybridizing to a complementary nucleic acid by Watson-Crick base pairing, whether DNA or RNA or a DNA-RNA hybrid, single-stranded or double-stranded, sense or antisense. Nucleic acids can also contain nucleotide analogs (e.g., BrdU) and non-phosphodiester internucleoside linkages (e.g., peptide nucleic acid (PNA) or thiodiester linkages). In particular, nucleic acids can include, but are not limited to, DNA, RNA, cDNA, gDNA, ssDNA, dsDNA, or any combination thereof.
[0031] As used herein, a "nucleotide" is a molecule containing a base moiety, a sugar moiety, and a phosphate moiety. Nucleotides can be linked together via their phosphate and sugar moieties to form an internucleoside linkage. The term "oligonucleotide" is sometimes used to refer to a molecule containing two or more linked nucleotides. The base moiety of a nucleotide can be adenine-9-yl (A), cytosine-1-yl (C), guanine-9-yl (G), uracil-1-yl (U), and thymin-1-yl (T). The sugar moiety of a nucleotide is ribose or deoxyribose. The phosphate moiety of a nucleotide is pentavalent phosphate. Non-limiting examples of nucleotides are 3'-AMP (3'-adenosine monophosphate) or 5'-GMP (5'-guanosine monophosphate).
[0032] Nucleotide analogs are nucleotides that contain certain modifications to the base, sugar, and / or phosphate moieties. Modifications to nucleotides are well known in the art and may include, for example, 5-methylcytosine (5-me-C), 5-hydroxymethylcytosine, xanthine, hypoxanthine, and 2-aminoadenine, as well as modifications at the sugar or phosphate moieties.
[0033] Nucleotide substitutes are molecules that have similar functional properties to nucleotides but do not contain a phosphate moiety, such as peptide nucleic acids (PNAs). Nucleotide substitutes are molecules that recognize nucleic acids via the Watson-Crick or Hoogsteen methods but are linked via a moiety other than the phosphate moiety. Nucleotide substitutes can adopt a double helix structure when interacting with an appropriate target nucleic acid.
[0034] The term "vector" or "construct" refers to a nucleic acid sequence capable of transporting into a cell another nucleic acid to which the vector sequence is linked. The term "expression vector" includes any vector (e.g., a plasmid, cosmid, or phage chromosome) that contains a genetic construct in a form suitable for expression by the cell (e.g., linked to a transcriptional regulatory element). Because plasmids are commonly used vector forms, the terms "plasmid" and "vector" are used interchangeably. Furthermore, the present invention is intended to include other vectors that perform equivalent functions.
[0035] The term "operably linked" refers to the functional relationship between a nucleic acid and another nucleic acid sequence. Promoters, enhancers, transcription and translation termination sites, and other signal sequences are examples of nucleic acid sequences that are operably linked to other sequences. For example, operably linking DNA to a transcriptional regulatory factor refers to a physical and functional association between the DNA and the promoter such that transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to, and transcribes the DNA.
[0036] For purposes herein, the % sequence identity of a given nucleotide or amino acid sequence C with or relative to a given nucleic acid sequence D (alternatively, it can be expressed as a given sequence C having or containing a particular % sequence identity with or relative to a given sequence D) is calculated as follows: 100 times the fraction W / Z where W is the number of nucleotides or amino acids scored as an identity match by the alignment of C and D in a sequence alignment program, and Z is the total number of nucleotides or amino acids in D. It will be understood that if the length of sequence C is not equal to the length of sequence D, then the % sequence identity of C to D will not be equal to the % sequence identity of D to C. Alignments for purposes of determining percent sequence identity can be obtained in a variety of ways within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2, or Megalign (DNASTAR) software.
[0037] By "specifically hybridize" is meant that a probe, primer, or oligonucleotide recognizes and physically interacts (i.e., base pairs) with a substantially complementary nucleic acid (e.g., a c-met nucleic acid) under conditions of high stringency, and does not substantially base pair with other nucleic acids.
[0038] As used herein, the term "stringent hybridization conditions" means that hybridization generally occurs when there is at least 95% and preferably at least 97% sequence identity between the probe sequence and the target sequence.An example of stringent hybridization conditions is overnight incubation in a solution containing 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20μg of denatured sheared carrier DNA such as salmon sperm DNA, followed by washing the hybridization support in 0.1x SSC at about 65℃.Other hybridization and washing conditions are well known and are exemplified in Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, NY (1989), especially Chapter 11.
[0039] Disclosed herein are compositions and methods for reprogramming skin cells into insulin-producing cells, both in vitro and in vivo.
[0040] composition Disclosed is a polynucleotide comprising a nucleic acid sequence encoding a protein selected from the group consisting of Pdx1, Ng3, Mafa, and Tcf3 ("PMN-T factors"). The amino acid and nucleic acid sequences encoding Pdx1, Ng3, Mafa, and Tcf3 are known in the art.
[0041] In some embodiments, Pdx1 is MNGEEQYYAATQLYKDPCAFQRGPAPEFSASPPACLYMGRQPPPPPPHPFPGALGALEQGSPPDISPYEVPPLADDPAVAHLHHHLPAQLALPHPPAGPFPEGAEPGVLEEPN RVQLPFPWMKSTKAHAWKGQWAGGAYAAEPEENKRTRTAYTRAQLLELEKEFLFNKYISRPRRVELAVMLNLTERHIKIWFQNRRMKWKKEEDKKRGGGTAVGGGGVAEPEQDC AVTSGEELLALPPPPPPGGAVPPAAPVAAREGRLPPGLSASPQPSSVAPRRPQEPR (SEQ ID NO: 1), or an amino acid sequence having at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1.
[0042] In some embodiments, the nucleic acid sequence encoding Pdx1 is (SEQ ID NO: 2), or a nucleic acid sequence that hybridizes to the nucleic acid sequence consisting of SEQ ID NO: 2 under stringent hybridization conditions.
[0043] In some embodiments, Ng3 has the amino acid sequence MTPQPSGAPTVQVTRETERSFPRASEDEVTCPTSAPPSPTRTRGNCAEAEEGGCRGAPRKLRARRGGRSRPKSELALSKQRRSRRKKANDRERNRMHNLNSALDALGVLPTFPDDAKLTKIETLRFAHNYIWALTQTLRIADHSLYALEPPAPHCGELGSPGGSPGDWGSLYSPVSQAGSLSPAASLEERPG LLGATSSACLSPGSLAFSDFL (SEQ ID NO: 3), or an amino acid sequence having at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 3.
[0044] In some embodiments, the nucleic acid sequence encoding Ng3 is (SEQ ID NO: 4), or a nucleic acid sequence that hybridizes to the nucleic acid sequence consisting of SEQ ID NO: 4 under stringent hybridization conditions.
[0045] In some embodiments, Mafa has the amino acid sequence MAAELAMGAELPSSPLAIEYVNDFDLMKFEVKKEPPEAERFCHRLPPGSLSSTPLSTPCSSVPSSPSFCAPSPGTGGGGGAGGGGGSQAGGAPGPPSGGPGAVGGTSGKPALEDLYWMSGYQHHLNPEAL NLTPEDAVEALIGSGHHGAHHGAHHPAAAAAYEAFRGPGFAGGGGADDMGAGHHHGAHHAAHHHHAAHHHHHHHHHHGGAGHGGGAGHHVRLEERFSDDQLVSMSVRELNRQLRGFSKEEVIRLKQKRRTL KNRGYAQSCRFKRVQQRHILESEKCQLQSQVEQLKLEVGRLAKERDLYKEKYEKLAGRGGPGSAGGAGFPREPSPPQAGPGGAKGTADFFL (SEQ ID NO:5), or an amino acid sequence having at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:5.
[0046] In some embodiments, the nucleic acid sequence encoding Mafa is
[0047] In some embodiments, Tcf3 has the amino acid sequence (SEQ ID NO:7), or an amino acid sequence having at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:7.
[0048] In some embodiments, Tcf3 has the amino acid sequence (SEQ ID NO:8), or an amino acid sequence having at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO:8.
[0049] In some embodiments, the nucleic acid sequence encoding Tcf3 is
[0050] In some embodiments, the nucleic acid sequence encoding Tcf3 is
[0051] To express a polypeptide or functional nucleic acid, the nucleotide coding sequence can be inserted into an appropriate expression vector. Thus, a non-viral vector is also disclosed, comprising a polynucleotide containing a nucleic acid sequence encoding two, three, or four proteins selected from the group consisting of Pdx1, Ng3, Mafa, and Tcf3, wherein the nucleic acid sequence is operably linked to an expression control sequence. In some embodiments, the nucleic acid sequence is operably linked to a single expression control sequence. In other embodiments, the nucleic acid sequence is operably linked to two or more separate expression control sequences.
[0052] Methods for constructing expression vectors containing gene sequences and appropriate transcriptional and translational control elements are well known in the art. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described in Sambrook et al., Molecular Cloning, A Laboratory Manual (Cold Spring Harbor Press, Plainview, NY, 1989) and Ausubel et al., Current Protocols in Molecular Biology (John Wiley & Sons, New York, NY, 1989).
[0053] Expression vectors generally contain regulatory sequences necessary for the translation and / or transcription of an inserted coding sequence. For example, the coding sequence is preferably operably linked to a promoter and / or enhancer that help control the expression of the desired gene product.
[0054] "Control elements" or "regulatory sequences" are untranslated regions of vector enhancers, promoters, 5' and 3' untranslated regions, etc., that interact with host cell proteins to carry out transcription and translation. Such elements can vary in their strength and specificity.
[0055] A "promoter" is generally a DNA sequence that functions when located in a relatively fixed position relative to the transcription start site. A "promoter" contains core elements required for basic interaction of RNA polymerase and transcription factors, and can contain upstream elements and response elements.
[0056] The term "enhancer" generally refers to a DNA sequence that functions at variable distances from the transcription start site and can be 5' or 3' to the transcription unit. Enhancers can also be found within introns or within the coding sequence itself. They are usually 10-300 bp long and function in cis. Enhancers function to increase transcription from nearby promoters. Like promoters, enhancers often contain response elements that mediate transcriptional regulation. Enhancers often determine expression regulation.
[0057] An "endogenous" enhancer / promoter is one that is naturally linked to a given gene in the genome. An "exogenous" or "heterologous" enhancer / promoter is one that is placed in juxtaposition to a gene by genetic engineering (i.e., molecular biological techniques) such that transcription of the gene is driven by the linked enhancer / promoter.
[0058] Promoters used in biotechnology are of different types depending on the intended type of control of gene expression and can generally be classified as constitutive promoters, tissue- or developmental stage-specific promoters, inducible promoters, and synthetic promoters.
[0059] Constitutive promoters drive expression in virtually all tissues and are largely, if not completely, independent of environmental and developmental factors. Because their expression is usually not conditioned by endogenous factors, constitutive promoters are usually active across species and even kingdoms. Examples of constitutive promoters include CMV, EF1a, SV40, PGK1, Ubc, human beta-actin, and CAG.
[0060] Tissue-specific or developmental stage-specific promoters direct gene expression in specific tissue(s) or at particular developmental stages. In plants, promoter elements that affect gene expression in the vascular system, photosynthetic tissues, tubers, roots, and other vegetative organs, or seeds and other reproductive organs can be found in heterologous systems (e.g., distantly related species or even other kingdoms), but the highest specificity is generally obtained using homologous promoters (i.e., promoters from the same species, genus, or family). This is likely because coordinated expression of transcription factors is required to regulate promoter activity.
[0061] The performance of inducible promoters is conditioned not only by endogenous factors but also by environmental conditions and external stimuli that can be artificially controlled. Within this group are promoters regulated by abiotic factors such as light, oxygen levels, heat, cold, and wounding. Because some of these factors are difficult to control outside of the experimental environment, promoters that respond to compounds not naturally found in the organism of interest are of particular interest. Along these lines, promoters that respond to antibiotics, copper, alcohols, steroids, and herbicides, among other compounds, have been adapted and refined to allow induction of gene activity at will, independent of other biotic or abiotic factors.
[0062] The two most commonly used inducible expression systems for eukaryotic cell biology research are termed Tet-Off and Tet-On. The Tet-Off system utilizes the tetracycline transactivator (tTA) protein, which is created by fusing one protein found in Escherichia coli bacteria, TetR (tetracycline repressor), with the activation domain of another protein, VP16, found in herpes simplex virus. The resulting tTA protein can bind to DNA at specific TetO operator sequences. In most Tet-Off systems, several repeats of such TetO sequences are placed upstream of a minimal promoter, such as the CMV promoter. The entire set of several TetO sequences with a minimal promoter is called a tetracycline response element (TRE), because it responds to the binding of the tetracycline transactivator protein tTA by increasing the expression of that gene or genes downstream of that promoter. In the Tet-Off system, expression of the TRE-controlled gene can be repressed by tetracycline and its derivatives. They bind to tTA, preventing it from binding to the TRE sequence, thereby preventing transactivation of the TRE-controlled gene. The Tet-On system works similarly, but in the reverse manner. In the Tet-Off system, tTA can bind to the operator only if it is not bound by tetracycline or one of its derivatives (such as doxycycline); in the Tet-On system, the rtTA protein can bind to the operator only if it is bound by tetracycline. Thus, introduction of doxycycline into the system initiates transcription of the gene product. The Tet-On system is sometimes preferred over the Tet-Off system due to its faster response.
[0063] In some embodiments, the nucleic acid sequences encoding Pdx1, Ng3, Mafa, and Tcf3 are operably linked to the same expression control sequence. Alternatively, an internal ribosome entry site (IRES) element can be used to generate multigene or polycistronic messages. The IRES element can bypass the ribosome scanning model of 5' methylated cap-dependent translation and initiate translation at an internal site. The IRES element can be linked to heterologous open reading frames. Multiple open reading frames can be transcribed together and separated by IRESs to generate polycistronic messages. Thanks to the IRES element, each open reading frame is accessible to ribosomes for efficient translation. Multiple genes can be efficiently expressed using a single promoter / enhancer to transcribe a single message.
[0064] Disclosed herein is a non-viral vector containing one or more polynucleotides disclosed herein, operably linked to an expression control sequence. Examples of such non-viral vectors include oligonucleotides alone or oligonucleotides combined with suitable protein, polysaccharide, or lipid formulations. Non-viral methods offer certain advantages over viral methods in that they are simple to produce on a large scale and have low host immunogenicity. Previously, non-viral methods were disadvantaged by low levels of gene transfection and expression, but recent advances in vector technology have led to molecules and technologies with transfection efficiencies similar to those of viruses.
[0065] Examples of suitable non-viral vectors include, but are not limited to, pIRES-hrGFP-2a, pCMV6, pMAX, pCAG, pAd-IRES-GFP, and pCDNA3.0.
[0066] The composition of the present disclosure can be used therapeutically in combination with a pharmaceutically acceptable carrier. " Pharmaceutically acceptable " refers to a material that can be administered to a subject together with a nucleic acid or vector without causing biologically or otherwise undesirable material, i.e., without causing undesirable biological effects or interacting in a harmful manner with any of the other components of the pharmaceutical composition in which it is contained.As is well known to those skilled in the art, a carrier will naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject.
[0067] Materials can be in solution, suspension (e.g., microparticles, liposomes, or incorporated into cells), and can be targeted to specific cell types via antibodies, receptors, or receptor ligands. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Senter, et al., Bioconjugate Chem., 2:447-451, (1991); Bagshawe, KD, Br. J. Cancer, 60:275-281, (1989); Bagshawe, et al., Br. J. Cancer, 58:700-703, (1988); Senter, et al., Bioconjugate Chem., 4:3-9, (1993); Battelli, et al., Cancer Immunol. Immunother., 35:421-425, (1992); Pietersz and McKenzie, Immunolog. Reviews, 129:57-80, (1992); and Roffler, et al. al., Biochem. Pharmacol, 42:2062-2065, (1991)). Vehicles such as "stealth" and other antibody-conjugated liposomes (including lipid-mediated drug targeting to colon cancer), receptor-mediated targeting of DNA with cell-specific ligands, lymphocyte-tropic tumor targeting, and highly specific therapeutic retroviral targeting of mouse glioma cells in vivo. The following references are examples of the use of this technology to target specific proteins to tumor tissue (Hughes et al., Cancer Research, 49:6214-6220, (1989), and Litzinger and Huang, Biochimica et Biophysica Acta, 1104:179-187, (1992)). In general, receptors are involved in pathways of endocytosis, either constitutive or ligand-induced. These receptors cluster into clathrin-coated pits, enter the cell via clathrin-coated vesicles, pass through acidified endosomes where the receptors are sorted, and then recycled to the cell surface, stored intracellularly, or degraded in lysosomes.Internalization pathways serve a variety of functions, including nutrient uptake, removal of activated proteins, export of macromolecules, opportunistic entry of viruses and toxins, ligand dissociation and degradation, and regulation of receptor levels. Many receptors follow more than one intracellular pathway, depending on cell type, receptor concentration, ligand type, ligand valency, and ligand concentration. The molecular and cellular mechanisms of receptor-mediated endocytosis have been reviewed (Brown and Greene, DNA and Cell Biology 10:6, 399-409 (1991)).
[0068] Suitable carriers and their formulations are described in Remington: The Science and Practice of Pharmacy (19th ed.) ed. A.R. Gennaro, Mack Publishing Company, Easton, PA 1995. Typically, an appropriate amount of a pharmaceutically acceptable salt is used in the formulation to render the formulation isotonic. Examples of pharmaceutically acceptable carriers include, but are not limited to, saline, Ringer's solution, and dextrose solution. The pH of the solution is preferably about 5 to about 8, more preferably about 7 to about 7.5. Additional carriers include sustained-release formulations, such as semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, liposomes, or microparticles. It will be apparent to those skilled in the art that certain carriers may be more preferable depending, for example, on the route of administration and concentration of the administered composition.
[0069] Pharmaceutical carriers are known to those skilled in the art.These will most typically be standard carriers for administering drugs to humans, including solutions such as sterile water, physiological saline, and buffer solutions at physiological pH.The composition can be administered intramuscularly or subcutaneously.Other compounds will be administered according to the standard procedures used by those skilled in the art.
[0070] Pharmaceutical compositions may include, in addition to the molecule of choice, carriers, thickeners, diluents, buffers, preservatives, surfactants, etc. Pharmaceutical compositions may also include one or more active ingredients such as antibacterial agents, anti-inflammatory agents, anesthetics, etc.
[0071] Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic / aqueous solutions, emulsions, or suspensions (including saline and buffered media). Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose, and sodium chloride, lactated Ringer's solution, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present, such as antibacterial agents, antioxidants, chelating agents, and inert gases.
[0072] Formulations for topical administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners, and the like may be necessary or desirable.
[0073] Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids, or binders may be desirable.
[0074] Some of the compositions are potentially administered as pharmaceutically acceptable acid or base addition salts, which may be formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanol amines.
[0075] The compositions disclosed herein, including pharmaceutical compositions, can be administered in several ways, depending on whether local or systemic treatment is desired and on the area to be treated.For example, the compositions of the present disclosure can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally.The compositions can be administered orally, parenterally (e.g., intravenously), by intramuscular injection, intraperitoneal injection, transdermally, extracorporeally, ophthalmically, vaginally, rectally, intranasally, topically, etc., including local intranasal administration or administration by inhalation.
[0076] method Also disclosed is a method for reprogramming skin cells into insulin-producing cells, comprising intracellularly delivering into the skin cells a polynucleotide comprising a nucleic acid sequence encoding Pdx1, Ng3, Mafa, and Tcf3. In some embodiments, the nucleic acid sequence is present in a non-viral vector. In some embodiments, the nucleic acid sequence is operably linked to an expression control sequence. In other embodiments, the nucleic acid is operably linked to two or more expression control sequences.
[0077] Various methods are known in the art and are suitable for introducing nucleic acid into cells, including viral and non-viral mediated methods.Typical non-viral mediated methods include but are not limited to electroporation, calcium phosphate mediated introduction, nucleofection, sonoporation, heat shock, magnetofection, liposome mediated introduction, microinjection, microprojectile mediated transfection (nanoparticle), cationic polymer mediated introduction (DEAE-dextran, polyethyleneimine, polyethylene glycol (PEG) etc.) or cell fusion.
[0078] In some embodiments, after transfecting target cells with PMN-T factors, the cells can load the transfected genes (e.g., cDNA) into EVs, which can then induce other somatic cells to form insulin-producing cells. Thus, a method for reprogramming skin cells into insulin-producing cells is also disclosed, comprising exposing somatic cells to extracellular vesicles containing or produced by Pdx1, Ng3, Mafa, and Tcf3.
[0079] Thus, a method for reprogramming skin cells into insulin-producing cells is disclosed, which includes exposing the skin cells to extracellular vesicles (EVs) isolated from cells that express or contain exogenous polynucleotides containing one or more nucleic acid sequences encoding Pdx1, Ng3, Mafa, and Tcf3. The EVs secreted by the donor cells can then be collected from the culture medium. These EVs can then be administered to skin cells to reprogram them into insulin-producing cells. In some embodiments, the donor cells can be any cells from a subject that can produce EVs, including, but not limited to, skin cells (e.g., fibroblasts, keratinocytes, skin stem cells), adipocytes, dendritic cells, peripheral blood mononuclear cells (PBMCs), pancreatic cells (e.g., ductal epithelial cells), liver cells (e.g., hepatocytes), and immune cells (e.g., T cells, macrophages, myeloid-derived suppressor cells).
[0080] Exosomes and microvesicles are distinct EVs based on their biogenesis and biophysical properties, including size and surface protein markers. Exosomes are small, homogeneous particles ranging in size from 40 to 150 nm and typically originate from the endocytic recycling pathway. During endocytosis, endocytic vesicles form at the plasma membrane and fuse to form early endosomes. These mature into late endosomes, where intraluminal vesicles bud into the intravesicular lumen. Instead of fusing with lysosomes, these multivesicular bodies fuse directly with the plasma membrane, releasing exosomes into the extracellular space. Exosome biogenesis, protein cargo sorting, and release involve endosomal sorting complexes required for transport (ESCRT complexes) and other associated proteins, such as Alix and Tsg101. In contrast, microvesicles are produced directly through the outward budding and fission of membrane vesicles from the plasma membrane; therefore, their surface markers depend heavily on the composition of the membrane of origin. Furthermore, they tend to comprise a larger, more heterogeneous population of extracellular vesicles, ranging in diameter from 150 to 1000 nm. However, both types of vesicles have been shown to deliver functional mRNA, miRNA, and proteins to recipient cells.
[0081] In some embodiments, polynucleotides can be delivered intracellularly to somatic cells of EVs or donor cells by gene guns, microparticles or nanoparticles suitable for such delivery, transfection by electroporation, three-dimensional nanochannel electroporation, tissue nanotransfection devices, liposomes suitable for such delivery, or deep local tissue nanoelectroinjection devices. In some embodiments, viral vectors can be used. However, in other embodiments, polynucleotides are not delivered virally.
[0082] Electroporation is a technique that applies an electric field to cells to increase the permeability of the cell membrane, allowing cargo (e.g., reprogramming factors) to be introduced into the cells. Electroporation is a common technique for introducing foreign DNA into cells.
[0083] Tissue nanotransfection enables direct cytosolic delivery of cargo (e.g., reprogramming factors) into cells by applying a very strong, focused electric field through arrayed nanochannels, thereby benignly nanoporating juxtaposed tissue cell members and electrophoretically driving the cargo into the cells.
[0084] In one embodiment, the compositions of the present disclosure are administered at a dose equivalent to parenteral administration of about 0.1 ng to about 100 g per kg body weight, about 10 ng to about 50 g per kg body weight, about 100 ng to about 1 g per kg body weight, about 1 μg to 100 mg per kg body weight, 1 μg to 50 mg per kg body weight, about 1 mg to about 500 mg per kg body weight, and 1 mg to about 50 mg per kg body weight. Alternatively, the amount of a composition of the present disclosure administered to obtain a therapeutically effective dose is about 0.1 ng, 1 ng, 10 ng, 100 ng, 1 μg, 10 μg, 100 μg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 500 mg, or more per kg of body weight.
[0085] The methods of the present disclosure can be used to treat various forms of diabetes. In some embodiments, the compositions and methods of the present disclosure are used to treat insulin-dependent (type 1) or insulin-resistant (type 2) diabetes in a subject. For example, the subject may have autoimmune diabetes, pancreatic resection-related diabetes, or metabolic syndrome that contributes to insulin resistance. In some embodiments, the compositions and methods of the present disclosure are used to treat gestational diabetes. In some cases, the methods can be used to treat subjects with prediabetes. The methods of the present disclosure can be used to treat diseases, disorders, or conditions affected by insulin deficiency, such as pancreatitis or pancreatic resection.
[0086] Although several embodiments of the present invention have been described, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims. [Example]
[0087] Example 1: Glycemic control in mice with type 1 diabetes induced by streptozotocin injection PBS baseline comparison Figures 1A-1E show the results of a study in which diabetic mice were treated once (by deep local nanoelectroinjection into the skin) with different gene cocktails. Blood glucose (y-axis) was measured from week 1 (post-treatment) through week 14 (x-axis). The results show that PNM-T cocktails delivered simultaneously or sequentially were able to support more controlled glucose levels (i.e., more similar to the baseline at which the mice started) compared to control / untreated mice and other permutations of the cocktails.
[0088] Although PNM genes (Pdx1, Ngn3, Mafa) have previously been reported to regulate the reprogramming of pancreatic ascinar cells into beta-like cells, no method has been developed for the successful non-viral reprogramming of skin tissue into insulin-producing tissue in vivo. Introduction of Tcf3, a transcription factor that plays a fundamental role in regulating skin plasticity, has enabled the development of skin-tailored reprogramming gene cocktails that can be delivered to the skin and facilitate the establishment of systemic normoglycemia in otherwise diabetic / hyperglycemic organisms.
[0089] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosed invention belongs. Publications cited herein and the material cited therein are specifically incorporated by reference.
[0090] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein which equivalents are intended to be encompassed by the following claims.
Claims
1. 1. A composition for use in a method for reprogramming skin cells of a subject into insulin-producing cells, the composition comprising a non-viral vector, the non-viral vector comprises a first nucleic acid sequence encoding Pdx1, a second nucleic acid sequence encoding Ngn3, a third nucleic acid sequence encoding Mafa, and a fourth nucleic acid sequence encoding Tcf3; The method comprises intracellularly delivering the composition into the skin cells of the subject.
2. The composition of claim 1 , wherein each of the first, second, third, and fourth nucleic acid sequences is operably linked to an expression control sequence.
3. The composition of claim 2 , wherein each of the first, second, third, and fourth nucleic acid sequences is operably linked to a single expression control sequence.
4. 4. The composition of claim 2 or 3, wherein the non-viral vector comprises a plasmid selected from the group of pIRES-hrGFP-2a, pCMV6, pMAX, pCAG, pAd-IRES-GFP, and pCDNA3.
0.
5. The composition of any one of claims 2 to 4, wherein the non-viral vector is encapsulated in a liposome, microparticle, or nanoparticle suitable for intracellular delivery.
6. 1. A composition comprising extracellular vesicles for use in a method for reprogramming skin cells in a subject into insulin-producing cells, the composition comprising: The extracellular vesicles are produced from cells that contain or express Pdx1, Ngn3, Mafa, and Tcf3 proteins; The method includes intracellular delivery of the extracellular vesicles into the skin cells by exposing the skin cells to the composition.
7. 1. A composition for use in a method for treating diabetes in a subject, comprising a non-viral vector, comprising: the non-viral vector comprises a first nucleic acid sequence encoding Pdx1, a second nucleic acid sequence encoding Ngn3, a third nucleic acid sequence encoding Mafa, and a fourth nucleic acid sequence encoding Tcf3; The method comprises administering the composition to the skin of the subject and reprogramming skin cells of the subject into insulin-producing cells.
8. The composition of claim 7 , wherein the subject has insulin-dependent diabetes.
9. The composition of claim 7 , wherein the subject has insulin-resistant diabetes.
10. The composition of claim 8 or 9, wherein the subject has a fasting blood glucose level of 70-130 mg / dL during treatment.
Citation Information
Patent Citations
Enhancement of glucose-stimulated insulin secretion by cells through induction of cellular senescence
US20170196913A1
Methods of reprogramming cells
WO2010022395A2
Compositions and methods for reprogramming somatic cells into induced vasculogenic cells
WO2018119091A1
